Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WanburyBOM:524212 -0.11%67 PB Ratio is 6.74 as of Aug. 05, 2026, which is 51% below its 10-year median of 13.88. GuruFocus rates BOM:524212 with a GF Score™ of 67/100 and a GF Value™ of ₹244.17 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Wanbury ranks worse than 89.91% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-05), Wanbury's share price is ₹278.80. Wanbury's Book Value per Share for the quarter that ended in Mar. 2026 was ₹41.34. Hence, Wanbury's PB Ratio of today is 6.74.
Warning Sign:
Wanbury Ltd stock PB Ratio (=8.04) is close to 1-year high of 8.56.
The historical rank and industry rank for Wanbury's PB Ratio or its related term are showing as below:
BOM:524212'
s PB Ratio Range Over the Past 10 Years
Min: 5.57 Med: 13.88 Max: 24.81
Current: 7.28
During the past 13 years, Wanbury's highest PB Ratio was 24.81. The lowest was 5.57. And the median was 13.88.
BOM:524212's PB Ratio is ranked worse than 89.91% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.915
vs BOM:524212: 7.28
During the past 12 months, Wanbury's average Book Value Per Share Growth Rate was 128.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Wanbury was 56.70% per year. The lowest was -33.80% per year. And the median was 7.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Wanbury PB Ratio Related Terms
Wanbury PB Ratio Historical Data
* Premium members only.
The historical data trend for Wanbury's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wanbury's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wanbury PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wanbury's PB Ratio distribution charts can be found below:
* The bar in red indicates where Wanbury's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Wanbury's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Wanbury (BOM:524212) has a PB Ratio of 6.74 as of Aug. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Wanbury and its competitors. This is 51% below median its historical median of 13.88. Over the past decade, Wanbury's PB Ratio has ranged from 5.57 to 24.81. According to the industry distribution chart, Wanbury ranks #829 out of 922 companies in the Drug Manufacturers industry, placing it in the top 89.9%.
Is Wanbury's PB Ratio too high?
Wanbury's current PB Ratio of 6.74 is 51% below median its 10-year median of 13.88. Over the past 10 years, this metric has ranged from a low of 5.57 to a high of 24.81. The Drug Manufacturers industry median PB Ratio is 1.92. Wanbury's value of 6.74 is 252% above this industry median. Based on the distribution chart, Wanbury ranks #829 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Wanbury has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wanbury's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wanbury ranks #829 out of 922 companies for PB Ratio. This places Wanbury in the lower half of its industry. The industry median PB Ratio is 1.92. Wanbury's value of 6.74 is 252% above this benchmark. Historically, Wanbury's own PB Ratio has ranged from 5.57 to 24.81 over the past decade. While the company's 10-year median is 13.88 vs. the industry median of 1.92, Wanbury has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.92, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wanbury's current PB Ratio of 6.74 is 252% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Wanbury and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wanbury's current PB Ratio is 6.74, which is 51% below median its own 10-year median of 13.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wanbury stock overvalued right now?
Based on GuruFocus' analysis, Wanbury (BOM:524212) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹244.17, compared to a current price of ₹278.80 — trading 14.2% above its estimated fair value. The current PB Ratio is 6.74, which is 51% below median its 10-year median of 13.88 and 252% above the Drug Manufacturers industry median of 1.92. Wanbury's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Wanbury (BOM:524212), the current PB Ratio is 6.74 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wanbury (BOM:524212) Overvalued in 2026?
Based on GuruFocus' analysis, Wanbury stock appears to be overvalued.
The current stock price of ₹278.80 is trading 14.2% above its estimated GF Value™ of ₹244.17.
GuruFocus considers Wanbury to be Modestly Overvalued.
Key valuation signals for BOM:524212:
PB Ratio: 6.74 (51% below median its 10-year median of 13.88)
GF Value™: ₹244.17 vs. price of ₹278.80 (14.2% above fair value)
Industry Position: 252% above the Drug Manufacturers median (#829 of 922)
No single metric tells the full story. See the BOM:524212 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wanbury Ltd is engaged in the business of pharmaceutical and related activities, including research. Some of the company's products include Cpink 50mg tablets, Rabiplus capsules, and Folinine softgels, among others. The company has one segment of activity, namely, Pharmaceuticals and related products. It generates revenue from contracts with customers through the sale of manufactured and traded goods. Geographically, key revenue is generated from outside India.
67GF Score
Get the complete analysis for BOM:524212
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524212 has been successfully added to your 
